BIIB122

Phase 3Small molecule

Biogen

BIIB122 is one of 52 small molecule programs targeting Movement Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Movement DisorderActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Movement DisorderPhase 3

Active, not recruiting

Inflammatory Bowel DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

151 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

OOrganon and Co

Phase 3

17 2

Stelara

Johnson & Johnson

Phase 3

1 3

Thalomid

Bristol-Myers Squibb

Phase 3

1 4

Farxiga

AstraZeneca

Phase 3

1 5

Humira

CCelltrion

Phase 3

7 6

Omvoh

Eli Lilly

Phase 3

—7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Lialda

1 10

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Parkinson's Disease

NCT06602193

Clinical

Trials by Indication[1]

Parkinson's Disease2 trials

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Active, not recruiting· Biogen logo

Biogen·Phase 2·NCT05348785·650 enrolled

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Recruiting·DDenali Therapeutics Inc.·Phase 2·NCT06602193·50 enrolled

Adult1 trial

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Completed· Biogen logo

Biogen·Phase 1·NCT05229562·84 enrolled

Tics1 trial

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Completed· Biogen logo

Biogen·Phase 1·NCT05119790·7 enrolled

Drug Interactions1 trial

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Completed· Biogen logo

Biogen·Phase 1·NCT06264440·18 enrolled

Movement Disorder1 trial

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated· Biogen logo

Biogen·Phase 3·NCT05418673·7 enrolled

1 more indication

Unspecified1 trial

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Completed· Biogen logo

Biogen·Phase 1·NCT05005338·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BIIB122. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIIB122 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIIB122. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Biogen

BIIB122

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Parkinson's Disease2 trials

Adult1 trial

Tics1 trial

Drug Interactions1 trial

Movement Disorder1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News